Tauroursodeoxycholate-d4-1
CAT:
804-HY-19696S2-01
Size:
1 mg
For Laboratory Research Only. Not for Clinical or Personal Use.
Price:
Ask
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


Tauroursodeoxycholate-d4-1
Description:
Tauroursodeoxycholate-d4-1 is the deuterium labeled Tauroursodeoxycholate. Tauroursodeoxycholate (Tauroursodeoxycholic acid) is an endoplasmic reticulum (ER) stress inhibitor. Tauroursodeoxycholate significantly reduces expression of apoptosis molecules, such as caspase-3 and caspase-12. Tauroursodeoxycholate also inhibits ERK.Product Name Alternative:
Tauroursodeoxycholic acid-d4-1; TUDCA-d4-1; UR 906-d4-1UNSPSC:
12352211Target:
Apoptosis; Caspase; Endogenous Metabolite; ERK; Isotope-Labeled CompoundsType:
Isotope-Labeled CompoundsRelated Pathways:
Apoptosis; MAPK/ERK Pathway; Metabolic Enzyme/Protease; Others; Stem Cell/WntApplications:
Metabolism-protein/nucleotide metabolismField of Research:
CancerSolubility:
10 mM in DMSOSmiles:
C[C@@]12[C@] (CC[C@]2 ([H]) [C@H] (C) CCC (NC ([2H]) ([2H]) C ([2H]) ([2H]) S (=O) (O) =O) =O) ([H]) [C@@]3 ([H]) [C@@] (CC1) ([H]) [C@@]4 ([C@] (C[C@@H] (CC4) O) ([H]) C[C@@H]3O) CMolecular Formula:
C26H41D4NO6SMolecular Weight:
503.73References & Citations:
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Kim SY, et al. Tauroursodeoxycholate (TUDCA) inhibits neointimal hyperplasia by suppression of ERK viaPKCα-mediated MKP-1 induction. Cardiovasc Res. 2011 Nov 1;92 (2) :307-16.|[3]Qin Y, et al. Tauroursodeoxycholic Acid Attenuates Angiotensin II Induced Abdominal Aortic Aneurysm Formation in Apolipoprotein E-deficient Mice by Inhibiting Endoplasmic Reticulum Stress. Eur J Vasc Endovasc Surg. 2017 Mar;53 (3) :337-345.Shipping Conditions:
Room temperatureScientific Category:
Isotope-Labeled CompoundsClinical Information:
No Development ReportedCAS Number:
2573035-17-1
